Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome: The VISTA-16 Randomized Clinical Trial

Overview of attention for article published in JAMA: Journal of the American Medical Association, January 2014

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

news: 9 news outlets
twitter: 32 X users
patent: 7 patents

facebook: 2 Facebook pages
wikipedia: 2 Wikipedia pages
reddit: 2 Redditors

Readers on

mendeley: 234 Mendeley

So far, Altmetric has seen 36 X posts from 32 X users, with an upper bound of 1,070,782 followers.

RT @PrivilegeHealth: Treating inflammation w/anti-inflammatory medications does not favorably change course and progression of disease. htt…

Treating inflammation w/anti-inflammatory medications does not favorably change course and progression of disease. http://t.co/kEmvPWclg5

Inhibidor de Fosfolipasa A2 ( Varespladip) incremento el riesgo de IAM. VISTA 16 trial. JAMA 2014 http://t.co/DU1Wmyklkv

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 32 additional X posts.